Compare ARK Genomic Revolution ETF (ARKG) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Ryanair Holdings plc — how do they compare? ARK Genomic Revolution ETF trades at $40.69, while Ryanair Holdings plc trades at $63.75 (market cap $31.76B). The key difference: Ryanair Holdings plc pays a 1.53% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Ryanair Holdings plc nearer its low. Which is the better fit depends on your goals.
| ARKG | RYAAY | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $73.82 |
52-Week Low | $23.09 | $53.24 |
Market Cap | — | $31.76B |
Enterprise Value | — | $29.42B |
Dividend Yield | — | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
RYAAY trades at $64.65, up 0.78% today, with a bullish technical signal and strong fundamentals including a 13.9 P/E ratio and 25.37% ROE. Recent earnings beat expectations in three of the last four quarters, and June 2026 traffic grew 7% year-over-year. The company maintains a debt-free balance sheet after repaying its final bond in May 2026, enhancing financial flexibility amid sector volatility.
Outlook remains positive with analyst consensus at 62.5% buy ratings, supported by robust operational execution and 80% fuel hedging for 2027. Key risks include rising operating costs, geopolitical tensions affecting fuel prices, and regulatory scrutiny over seating policies. The stock's valuation appears reasonable relative to earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
